March 28, 2021 – Recent reports from the United Kingdom (UK) and from throughout the European Union (EU) have suggested that the SARS-CoV-2 (Covid-19) vaccine made by AstraZeneca was at the origin of the development of a very rare type …

Covid-19 Vaccines: Is there genetic predisposition for thrombosis? Read more »

Tagged with: , , , , , , , , , , , ,

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), and T-cell …

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients Read more »

Tagged with: , , , , , , ,

November 08, 2018 –  The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients. Thus, FDA permits marketing, with special controls, the …

Living theragenomic medicine: Direct to consumer test for metabolism of drugs FDA approved Read more »

Tagged with: , , , , , , , , , , , , , , , ,

January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients.   The American Food & Drug Administration (FDA) just approved Lutetium (Lu …

Lutetium 177 dotatate (Lutathera): A treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Read more »

Tagged with: , , , , , , ,

 December 16, 2017 – As recent as of December 14, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the …

X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue Read more »

Tagged with: , , , , , , , ,

August 18, 2017 – B-cell precursor acute lymphoblastic leukemia (ALL) is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. In the United States, …

Besponsa: Is this really a viable new treatment for ALL? Read more »

Tagged with: , , , , , , , , , , ,

September 30, 2016 – This is very good news for patients suffering from any form of a rare disease. The European Medicines Agency (EMA) and the American Food and Drug Administration (FDA) have engaged in a joint effort to boost development of …

Rare diseases: EU and US collaborate to boost development of therapies Read more »

Tagged with: , , , , ,

 September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 …

Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU Read more »

Tagged with: , , , , , , , , , , , , ,

August 08, 2016 –The following publication has just been released by the EMA. Because Thasso Post is not only about theragenomic and personalized medicine, but also about the safety of medicines for each individual patient, thasso feels that this is …

Patient safety: EMA recommends suspension of medicines over flawed studies Read more »

Tagged with: , , , ,

 June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block …

With Infliximab (Flixabi), a huge biosimilar medicine has been approved in the European Union (EU) Read more »

Tagged with: , , , , , , , , , , , ,